Drug Profile
VB 2011
Alternative Names: H-11; H-11 scFv; Novomab-G2 scFv; VB2-011Latest Information Update: 12 Feb 2007
Price :
$50
*
At a glance
- Originator Viventia Biotech
- Developer University of Alabama at Birmingham
- Class Antibody diagnostics; Antineoplastics; Immunoglobulin Fv fragments
- Mechanism of Action Antibody-dependent cell cytotoxicity; Diagnostic imaging enhancers; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Cancer; Lymphoma; Malignant melanoma; Non-Hodgkin's lymphoma; Solid tumours